Health Canada drug identification number

DIN 02459795 — XOLAIR 150 MG

XOLAIR is a solution of Omalizumab marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Omalizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.

DIN
02459795
Brand name
XOLAIR
Active ingredient
Omalizumab
Strength
150 MG
Dosage form
SOLUTION
Route
SUBCUTANEOUS
Manufacturer
NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status
MARKETED
Drug class
IgE-neutralizing antibody (anti-IgE monoclonal antibody)

Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.

Other Omalizumab products

DINBrandStrengthFormManufacturerStatus
02553813 OMLYCLO 150 MG SOLUTION CELLTRION INC. MARKETED
02561026 OMLYCLO 150 MG SOLUTION CELLTRION INC. MARKETED
02553805 OMLYCLO 75 MG SOLUTION CELLTRION INC. MARKETED
02561018 OMLYCLO 75 MG SOLUTION CELLTRION INC. MARKETED
02260565 XOLAIR 150 MG POWDER FOR SOLUTION NOVARTIS PHARMACEUTICALS CANADA INC MARKETED
02545144 XOLAIR 150 MG SOLUTION NOVARTIS PHARMACEUTICALS CANADA INC MARKETED
02545160 XOLAIR 300 MG SOLUTION NOVARTIS PHARMACEUTICALS CANADA INC MARKETED
02459787 XOLAIR 75 MG SOLUTION NOVARTIS PHARMACEUTICALS CANADA INC MARKETED
02545136 XOLAIR 75 MG SOLUTION NOVARTIS PHARMACEUTICALS CANADA INC MARKETED

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.